Ponatinib is a tyrosine kinase inhibitor drug that is used in the treatment of certain types of leukemia, particularly chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It works by blocking the action of abnormal proteins that promote the growth of cancer cells. Ponatinib is typically prescribed when other treatments have been ineffective or if the patient has developed resistance to other tyrosine kinase inhibitors. It is taken orally in the form of a pill and is usually well-tolerated, although it can have side effects such as high blood pressure, fatigue, and abdominal pain. Research on ponatinib is ongoing to further understand its effectiveness, safety, and potential applications in treating other types of cancer. Studies are also being conducted to investigate combination therapies with ponatinib to improve outcomes for patients with leukemia.